Pour les tics et tocs, serait-ce SLITRK1 ? - Archive ouverte HAL Access content directly
Journal Articles Médecine/Sciences Year : 2005

Pour les tics et tocs, serait-ce SLITRK1 ?


Type 2 diabetes is characterized by two major defects: a dysregulation of pancreatic hormone secretion (quantitative and qualitative--early phase, pulsatility--decrease of insulin secretion, increase in glucagon secretion), and a decrease in insulin action on target tissues (insulin resistance). The defects in insulin action on target tissues are characterized by a decreased in muscle glucose uptake and by an increased hepatic glucose production. These abnomalities are linked to several defects in insulin signaling mechanisms and in several steps regulating glucose metabolism (transport, key enzymes of glycogen synthesis or of mitochondrial oxidation). These postreceptors defects are amplified by the presence of high circulating concentrations of free fatty acids. The mechanisms involved in the "diabetogenicity" of long-chain fatty acids are reviewed in this paper. Indeed, elevated plasma free fatty acids contribute to decrease muscle glucose uptake (mainly by reducing insulin signaling) and to increase hepatic glucose production (stimulation of gluconeogenesis by providing cofactors such as acetyl-CoA, ATP and NADH). Chronic exposure to high levels of plasma free fatty acids induces accumulation of long-chain acyl-CoA into pancreatic beta-cells and to the death of 50% of beta-cell by apoptosis (lipotoxicity).
Fichier principal
Vignette du fichier
DerniereHeure_1_.pdf.PDF (71.41 Ko) Télécharger le fichier

Dates and versions

inserm-00103694 , version 1 (05-10-2006)


  • HAL Id : inserm-00103694 , version 1
  • PUBMED : 16324657


Jacques Epelbaum. Pour les tics et tocs, serait-ce SLITRK1 ?. Médecine/Sciences, 2005, 21 (12), pp.1117. ⟨inserm-00103694⟩


69 View
111 Download



Gmail Facebook Twitter LinkedIn More